{"entity":{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","aka":["JTO","J Thorac Oncol"],"tldr":"The Journal of Thoracic Oncology is the IASLC's journal and the leading specialist venue for lung cancer and mesothelioma: staging, biomarkers, targeted-therapy and screening research.","summary":"Publishes the IASLC TNM staging proposals, lung-cancer screening implementation studies, biomarker testing guidelines and phase 2 trials and long-term follow-up in EGFR, ALK, KRAS and other molecularly defined lung cancers. Hybrid access via Elsevier; the World Conference on Lung Cancer abstracts appear here.","asOf":"2026-09-09","links":[{"label":"IASLC","url":"https://www.iaslc.org"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.jto.org","issn":"1556-0864","scope":"thoracic oncology","access":"hybrid","founded":2006,"impactFactor":{"value":21,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Journal of Thoracic Oncology","JTO","J Thorac Oncol"],"society":"International Association for the Study of Lung Cancer"},"route":"/journals/journal-of-thoracic-oncology/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"paper":[{"id":"paper-adaura-8-year-os-jto-2026","kind":"paper","name":"ADAURA: exploratory eight-year overall survival update for adjuvant osimertinib in resected EGFR-mutated stage IB to IIIA lung cancer","route":"/key-papers/paper-adaura-8-year-os-jto-2026/"},{"id":"paper-nct06015503-j-thorac-oncol-2026","kind":"paper","name":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study","route":"/key-papers/paper-nct06015503-j-thorac-oncol-2026/"},{"id":"paper-camidge-j-thorac-oncol","kind":"paper","name":"Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial","route":"/key-papers/paper-camidge-j-thorac-oncol/"},{"id":"paper-camel-j-thorac-oncol-2023-update","kind":"paper","name":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","route":"/key-papers/paper-camel-j-thorac-oncol-2023-update/"},{"id":"paper-nct03381274-j-thorac-oncol-2023","kind":"paper","name":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","route":"/key-papers/paper-nct03381274-j-thorac-oncol-2023/"},{"id":"paper-offin-rb1-tp53-transformation-risk-jto-2019","kind":"paper","name":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","route":"/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/"},{"id":"paper-li-j-thorac-oncol","kind":"paper","name":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results","route":"/key-papers/paper-li-j-thorac-oncol/"},{"id":"paper-nct05955391-j-thorac-oncol-2026","kind":"paper","name":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","route":"/key-papers/paper-nct05955391-j-thorac-oncol-2026/"},{"id":"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022","kind":"paper","name":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","route":"/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/"},{"id":"paper-nct03775486-j-thorac-oncol-2023","kind":"paper","name":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","route":"/key-papers/paper-nct03775486-j-thorac-oncol-2023/"},{"id":"paper-nct03003962-j-thorac-oncol-2025","kind":"paper","name":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study","route":"/key-papers/paper-nct03003962-j-thorac-oncol-2025/"},{"id":"paper-zhou-j-thorac-oncol","kind":"paper","name":"Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study","route":"/key-papers/paper-zhou-j-thorac-oncol/"},{"id":"paper-orient-11-j-thorac-oncol-2020","kind":"paper","name":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)","route":"/key-papers/paper-orient-11-j-thorac-oncol-2020/"},{"id":"paper-nct06120140-j-thorac-oncol-2025","kind":"paper","name":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial","route":"/key-papers/paper-nct06120140-j-thorac-oncol-2025/"},{"id":"paper-destiny-lung02-j-thorac-oncol-2025","kind":"paper","name":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC","route":"/key-papers/paper-destiny-lung02-j-thorac-oncol-2025/"},{"id":"paper-nct05186974-j-thorac-oncol-2026","kind":"paper","name":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study","route":"/key-papers/paper-nct05186974-j-thorac-oncol-2026/"},{"id":"paper-kozono-j-thorac-oncol","kind":"paper","name":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)","route":"/key-papers/paper-kozono-j-thorac-oncol/"},{"id":"paper-hirsch-j-thorac-oncol","kind":"paper","name":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","route":"/key-papers/paper-hirsch-j-thorac-oncol/"},{"id":"paper-blueprint-phase-2-pd-l1-assays-jto-2018","kind":"paper","name":"PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project","route":"/key-papers/paper-blueprint-phase-2-pd-l1-assays-jto-2018/"},{"id":"paper-nct05663866-j-thorac-oncol-2025","kind":"paper","name":"Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report","route":"/key-papers/paper-nct05663866-j-thorac-oncol-2025/"},{"id":"paper-nct02411448-j-thorac-oncol-2025-update","kind":"paper","name":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC","route":"/key-papers/paper-nct02411448-j-thorac-oncol-2025-update/"},{"id":"paper-baine-sclc-subtype-immunohistochemistry-jto-2020","kind":"paper","name":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","route":"/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/"},{"id":"paper-nct04665856-j-thorac-oncol-2026","kind":"paper","name":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China","route":"/key-papers/paper-nct04665856-j-thorac-oncol-2026/"},{"id":"paper-nct05168566-j-thorac-oncol-2026","kind":"paper","name":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial","route":"/key-papers/paper-nct05168566-j-thorac-oncol-2026/"},{"id":"paper-lung-map-j-thorac-oncol-2019","kind":"paper","name":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)","route":"/key-papers/paper-lung-map-j-thorac-oncol-2019/"},{"id":"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022","kind":"paper","name":"The 2021 WHO classification of tumours of the thymus and mediastinum: what is new in thymic epithelial, germ cell and mesenchymal tumours","route":"/key-papers/paper-who-2021-thymus-mediastinum-classification-marx-jto-2022/"},{"id":"paper-pharos-j-thorac-oncol-2025","kind":"paper","name":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report","route":"/key-papers/paper-pharos-j-thorac-oncol-2025/"},{"id":"paper-lindeman-lung-molecular-testing-guideline-jto-2018","kind":"paper","name":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors","route":"/key-papers/paper-lindeman-lung-molecular-testing-guideline-jto-2018/"}],"person":[{"id":"corinne-faivre-finn","kind":"person","name":"Corinne Faivre-Finn","route":"/people/corinne-faivre-finn/"},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/"},{"id":"valerie-rusch","kind":"person","name":"Valerie W. Rusch","route":"/people/valerie-rusch/"}]}}